Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study

Tadashi Terui,Yukari Okubo,Satomi Kobayashi,Shigetoshi Sano,Akimichi Morita,Shinichi Imafuku,Yayoi Tada,Masatoshi Abe,Masafumi Yaguchi,Natsuka Uehara,Takahiro Handa,Masayuki Tanaka,Wendy Zhang,Maria Paris,Masamoto Murakami

Journal of the American Academy of Dermatology（2023）

引用 1|浏览2

暂无评分

摘要

Background: Palmoplantar pustulosis (PPP) is a pruritic, painful chronic dermatitis, and approved therapeutic options are limited. This randomized, phase 2 study (NCT04057937) evaluated apremilast 30 mg BID (APR) efficacy and safety vs placebo (PBO) for moderate to severe PPP after inadequate response to topical therapy in Japan.

查看译文

关键词

palmoplantar pustulosis,apremilast,treatment,japanese patients,placebo-controlled

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要